PRAX-114 Drug Market
PRAX-114 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about PRAX-114 for Major Depressive Disorder (MDD) in the seven major markets. A detailed picture of the PRAX-114 for MDD in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 –2032 is provided in this report along with a detailed description of the PRAX-114 for MDD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the PRAX-114 market forecast analysis for MDD in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in MDD.
PRAX-114 Drug Summary
PRAX-114 is a potentially differentiated GABAA receptor PAM currently in Phase IIa development for the treatment of MDD. Based on early clinical data, a marked improvement in depression scores in MDD patients within 2 weeks of treatment was observed. The company intends to develop PRAX-114 in the United States and other countries as both a monotherapy and adjunctive therapy for MDD and PMD in acute and maintenance settings.
In June 2022, Praxis Precision Medicines announced that the Phase 2/3 Aria Study evaluating the efficacy and safety of PRAX-114 for monotherapy treatment of major depressive disorder (MDD) did not achieve statistical significance on the primary endpoint of change from baseline in the 17-item Hamilton Depression Rating Scale (HAM-D17) total score at Day 15, or on any secondary endpoints.
Scope of the PRAX-114 Drug Market Report
The report provides insights into:
• A comprehensive product overview including the PRAX-114 description, mechanism of action, dosage and administration, research and development activities in MDD.
• Elaborated details on PRAX-114 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the PRAX-114 research and development activities in MDD across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around PRAX-114.
• The report contains forecasted sales of PRAX-114 for MDD till 2032.
• Comprehensive coverage of the late-stage emerging therapies for MDD.
• The report also features the SWOT analysis with analyst views for PRAX-114 in MDD.
PRAX-114 Methodology
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
PRAX-114 Analytical Perspective by DelveInsight
• In-depth PRAX-114 Market Assessment
This report provides a detailed market assessment of PRAX-114 for MDD in the seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
• PRAX-114 Clinical Assessment
The report provides the clinical trials information of PRAX-114 for MDD covering trial interventions, trial conditions, trial status, start and completion dates.
PRAX-114 Drug Market Report Highlights
• In the coming years, the market scenario for MDD is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence PRAX-114 dominance.
• Other emerging products for MDD are expected to give tough market competition to PRAX-114 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of PRAX-114 in MDD.
• Our in-depth analysis of the forecasted sales data of PRAX-114 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the PRAX-114 in MDD.
Key Questions
• What is the product type, route of administration and mechanism of action of PRAX-114?
• What is the clinical trial status of the study related to PRAX-114 in MDD and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the PRAX-114 development?
• What are the key designations that have been granted to PRAX-114 for MDD?
• What is the forecasted market scenario of PRAX-114 for MDD?
• What are the forecasted sales of PRAX-114 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to PRAX-114 for MDD?
• Which are the late-stage emerging therapies under development for the treatment of MDD?
